Every 8-K that Exicure, Inc. (XCUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XCUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XCUR filings page.
Exicure, Inc. is reshaping its board and governance structure. Director Ham Jung Kyu resigned from the Board effective June 30, 2026. The Board size will increase from five to six directors on the same date, expanding the number of Class III directors.
To fill the resulting seats, the Board appointed Han Eui Seok and Go Jin Young as Class III directors, effective June 30, 2026. The Board determined that Mr. Han qualifies as an independent director under Nasdaq Listing Rule 5605(a)(2), while Mr. Go does not, due to his anticipated role as a non-independent director.
The Board also created a new Compensation Committee, effective June 30, 2026, naming Mr. Han as Chair and Dongho Lee as a member. The company states there are no related-party transactions, special arrangements, or family relationships involving the new directors that require disclosure.
Exicure, Inc. reported that Nasdaq notified the company on May 28, 2026 that it was out of compliance with Nasdaq Listing Rule 5250(c)(1) because its Form 10-Q for the quarter ended March 31, 2026 was filed late.
The delay was attributed to extra time needed after changes in Exicure’s financial reporting personnel and related procedures. Exicure filed the delayed Form 10-Q on May 29, 2026 and believes this filing brings it back into compliance with the Nasdaq listing rule.
The company describes itself as a biotechnology business that has restructured, suspended prior clinical and development activities, and is now exploring strategic alternatives. Its lead program, obtained through a January 2025 acquisition, is being evaluated for improving stem cell mobilization in multiple myeloma, sickle cell disease, and to support cell and gene therapy.
Exicure, Inc. reported governance and management changes, including a new director and a new Chief Operating Officer. These updates focus on strengthening board oversight and operational leadership.
The Board appointed Yoontae Han as director and Audit Committee member, with an annual retainer of $20,000. It also named Dongho Lee as Chair of the Audit Committee. Separately, effective April 9, 2026, Exicure appointed Young Seung Ko, age 50, as Chief Operating Officer and amended its executive services agreement with Innocircle Advisors Inc. to add an extra monthly fee of $10,000 for COO services.
Exicure, Inc. has obtained preliminary court approval for a global settlement of stockholder derivative matters tied to previously disclosed litigation over past handling of research data and disclosures. The settlement covers actions in federal courts in Illinois and Delaware plus a stockholder demand to the board.
Under the proposed terms, Exicure will adopt and maintain a package of corporate governance reforms for at least four years, including a new board-level Research and Data Integrity Oversight Committee and a management-level Disclosure Committee. Defendants’ insurers, rather than the company, have agreed to pay $675,000 in plaintiffs’ attorneys’ fees and expenses, subject to final court approval. A settlement hearing is scheduled for June 2, 2026, and current stockholders as of March 18, 2026 may object by written submission ahead of that date.
Exicure, Inc. reported a change on its Board of Directors. On March 25, 2026, director Sangjin Yeo submitted his resignation from the Board and the Audit Committee, effective March 27, 2026. The company stated that his resignation did not result from any disagreement regarding its operations, policies, or practices. The report was signed on behalf of Exicure by Chief Executive Officer Jung Soo Kim.
Exicure, Inc. reported a smaller net loss for 2025 but highlighted serious liquidity challenges. Net loss narrowed to $4.9 million from $9.7 million in 2024, helped by a $6.0 million gain from early termination of its Chicago office lease.
Cash and cash equivalents fell sharply to $3.7 million as of December 31, 2025, from $12.5 million a year earlier. Management states this cash is not sufficient to fund operations, and that substantial additional financing is needed in the short term to pay expenses and continue exploring strategic alternatives.
Following the acquisition of GPCR Therapeutics USA Inc., research and development expenses rose to $3.3 million from zero, while general and administrative expense increased to $6.8 million from $5.4 million, mainly due to acquisition and integration costs. Revenue was $0 in 2025 versus $0.5 million in 2024.
Exicure, Inc. reported a leadership change, appointing Jung Soo Kim as Chief Executive Officer and President and Gyuyeob Lee as Interim Chief Financial Officer and Secretary, effective February 11, 2026. These appointments follow the resignations of former CEO and President Andy Yoo and former CFO and Secretary Seung Ik Baik, effective February 9, 2026.
The company highlights Mr. Kim’s more than 20 years of experience in corporate strategy, capital markets and restructuring, and Mr. Lee’s background in governance restructuring, financial planning and regulatory compliance, including their current roles at AGEDB Technology. Exicure’s board also approved that CEO and Interim CFO services will be provided under executive services agreements with Innocircle Advisors Inc.
Exicure, Inc. reported significant leadership and board changes. On February 6, 2026, three directors — Andy Yoo, Seung Ik Baik, and Aejin Hwang — resigned from the Board effective February 9, 2026, with the company stating there were no disagreements over operations or policies.
The Board simultaneously appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon as new directors, with staggered terms through the 2026, 2027, and 2028 annual meetings, and named Mr. Cheon to the audit committee. Each new director will receive a $20,000 annual retainer.
The Board also approved a one-time $20,000 cash payment to each of the two remaining directors, Dongho Lee and Sangjin Yeo, and to outgoing director Hwang. On the same date, Yoo resigned as Chief Executive Officer and President, and Baik resigned as Chief Financial Officer and Secretary, effective February 9, 2026. The Board has not yet appointed successors, and Baik received a $150,000 separation payment.
Exicure, Inc. reported achieving the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., tied to completing a Phase 2 clinical trial of its novel stem cell mobilizer (CXCR4 inhibitor Burixafor, GPC‑100). The milestone was reached when the Clinical Study Report was formally submitted to the U.S. Food and Drug Administration on January 16, 2026. Under the agreement, Exicure must pay $1,000,000 to GPCR Therapeutics within 30 days, and completion of this milestone also triggers a future sublicensing income‑sharing ratio that increases Exicure’s participation in the long‑term economics of the program.
Exicure, Inc. reported that on November 10, 2025 it redeemed in full 4.5 billion KRW (approximately $3.125 million) of 2.90% Convertible Bonds due 2028. These bonds were originally issued on April 30, 2025 by its wholly owned subsidiary KC Creation Co., Ltd. and were held entirely by Exicure, with no third-party holders involved. The redemption was funded through internal cash transfers as part of an effort to simplify intercompany financing and secure liquidity for ongoing biotechnology operations. Because this is an internal transaction between Exicure and its subsidiary, it will be eliminated in consolidation and is not expected to have a material impact on Exicure’s consolidated financial statements.
Exicure, Inc. (XCUR) reported 2025 annual meeting results. Stockholders elected two Class II directors to serve until the 2028 annual meeting. Sangjin Yeo received 3,481,839 votes for and 1,039 withheld; Aejin Hwang received 3,481,839 for and 1,039 withheld. There were 293,024 broker non-votes and no abstentions for Proposal 1.
Stockholders ratified CBIZ CPAs P.C. as the independent auditor for the year ending December 31, 2025, with 3,750,205 votes for, 12,485 against, and 13,212 abstentions. The advisory vote on executive compensation was approved with 3,478,408 votes for, 3,931 against, and 539 abstentions, with 293,024 broker non-votes.
Exicure, Inc. (XCUR) announced quarterly results via an 8‑K. On November 7, 2025, the company reported that a press release detailing financial and operational results for the quarter ended September 30, 2025 was furnished under Item 2.02. The press release is included as Exhibit 99.1 and, as furnished information, is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless specifically stated. The filing was signed by Chief Executive Officer Andy Yoo.
Exicure, Inc. reported significant changes to its Board of Directors. On September 8, 2025, the company appointed Sangjn Yeo and Aejin Hwang as Class II directors, with terms running until the 2025 annual meeting of stockholders or until a successor is elected and qualified. Both were also named to the audit committee, and Mr. Yeo was appointed Chairman of that committee.
The filing states there are no family relationships between the new directors and existing leadership, and no material related-party transactions requiring disclosure. Each new director will receive an annual retainer of $20,000 and is expected to enter into the company’s standard indemnification agreement.
Also on September 8, 2025, four directors — Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang — resigned from the Board, effective immediately. Their resignations were not due to any disagreement about the company’s operations, policies, or practices. After these appointments and resignations, Exicure has four remaining vacancies on its Board.
Exicure, Inc. (XCUR) furnished a press release on August 8, 2025 announcing its financial and operational results for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report on Form 8-K. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and explicitly is not to be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into registration statements except by specific reference.
This filing does not include the text of the earnings release or any financial tables within the 8-K itself; it confirms only that results were announced and that the press release is attached as an exhibit to the report.
Exicure, Inc. (Nasdaq: XCUR) filed a Form 8-K dated June 27, 2025 to furnish its financial and operational results for the quarter ended March 31, 2025. The disclosure falls under Item 2.02 – Results of Operations and Financial Condition and simply states that a detailed press release is attached as Exhibit 99.1. Because the information is "furnished" rather than "filed," it is not subject to Section 18 liability and will not be incorporated by reference unless explicitly cited in a future registration statement.
No revenue, earnings, cash-flow figures or guidance appear in the 8-K text provided, and no additional items such as material transactions or strategic updates are included. The only other exhibit is Exhibit 104, the standard Inline XBRL cover-page data file. All remaining content—registration details, securities listing, emerging-growth-company status, and officer signature—matches routine SEC formatting.
Key takeaway for investors: today’s 8-K serves as a procedural notice that the Q1 2025 results press release is now available. Investors must review Exhibit 99.1 to assess the actual performance metrics and forward-looking commentary.